Feb 18, 2026 07:00AM
Feb 18, 2026 07:00AM
Jan 7, 2026 06:30PM
Sep 11, 2025 07:02AM
Sep 11, 2025 07:00AM
Jul 25, 2025 08:00AM
Jul 25, 2025 08:00AM KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
Jul 15, 2025 04:05PM
Jul 15, 2025 04:05PM
Jul 11, 2025 06:37AM
Jul 10, 2025 10:29AM
Jul 10, 2025 07:00AM
Jul 7, 2025 02:40PM
Jul 7, 2025 06:31AM FDA approves KalVista's (KALV) oral HAE treatment EKTERLY
Jul 7, 2025 06:30AM
Jul 2, 2025 04:05PM
Jun 26, 2025 07:02AM
Jun 26, 2025 07:00AM
Jun 24, 2025 03:50PM
Jun 24, 2025 01:57PM
Jun 16, 2025 07:28AM Stifel Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
Jun 16, 2025 07:03AM
Jun 16, 2025 07:00AM
Jun 16, 2025 04:19AM
Jun 13, 2025 04:06PM
Jun 13, 2025 04:05PM
Jun 5, 2025 07:00AM
Jun 3, 2025 04:01PM KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2025 07:00AM
May 29, 2025 07:00AM
May 22, 2025 07:00AM
May 2, 2025 07:00AM
Apr 30, 2025 07:00AM
Apr 8, 2025 06:31AM
Apr 8, 2025 06:30AM KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
Apr 2, 2025 07:00AM
Mar 31, 2025 07:00AM
Mar 25, 2025 07:02AM
Mar 25, 2025 07:00AM
Mar 12, 2025 07:00AM
Mar 10, 2025 07:00AM
Mar 4, 2025 07:00AM KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 3, 2025 07:05AM
Mar 3, 2025 07:00AM
Feb 24, 2025 07:00AM
Feb 21, 2025 07:00AM
Feb 10, 2025 07:00AM
Feb 4, 2025 07:00AM
Jan 21, 2025 07:01AM KalVista Pharmaceuticals (KALV) Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
Jan 21, 2025 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All